GLP-1 Weight-Loss Drugs and Heart Disease: What the Latest Evidence Means for Patients in 2026

Why heart patients are hearing about GLP-1 drugs in 2026

If you have heart disease, you have probably heard about GLP-1 medications such as semaglutide (brand name Wegovy). Originally developed for diabetes and later approved for chronic weight management, semaglutide is now also approved in the United States to reduce the risk of major cardiovascular events in certain high-risk adults.

The reason is a large, high-quality clinical trial called SELECT. For many heart patients, this was the first time a weight-loss medication showed clear evidence of lowering the risk of heart attack and stroke in people without diabetes.

But eligibility is specific. Coverage is uneven. And the drug does not replace standard heart medications. Here is what the evidence actually shows—and what it means for patients in the U.S. in 2026.

What the SELECT trial actually showed

The SELECT trial, published in The New England Journal of Medicine in 2023, was a large randomized, placebo-controlled cardiovascular outcomes trial. That means participants were randomly assigned to receive semaglutide or a placebo, and researchers tracked major heart outcomes over time.

Who was studied?

More than 17,000 adults
Overweight or obesity (body mass index 27 or higher)
Established cardiovascular disease (such as prior heart attack, stroke, or peripheral artery disease)
No diabetes

This was mostly a secondary prevention population—people who already had cardiovascular disease. The results do not automatically apply to people without heart disease.

What was the main outcome?

The primary endpoint was major adverse cardiovascular events (often called “MACE”), a combined measure of:

Cardiovascular death
Nonfatal heart attack
Nonfatal stroke

Over a median follow-up of about 3.5 years, semaglutide reduced the relative risk of these events by about 20% compared with placebo.

In absolute terms, about 8.0% of people in the semaglutide group experienced a major cardiovascular event compared with 9.8% in the placebo group. That is an absolute difference of roughly 1.8 percentage points over the study period.

In practical terms: for every 100 high-risk patients like those in the trial treated for several years, about two major cardiovascular events were prevented.

Participants also lost significantly more weight on semaglutide than placebo. However, researchers believe the heart benefits likely reflect multiple effects—not just weight loss, but also changes in inflammation, blood pressure, and metabolism. The exact mechanisms are still being studied.

Important limitations

The study included people with established cardiovascular disease, not the general population.
People with diabetes were excluded.
Follow-up was just over three years; longer-term durability beyond that timeframe remains under study.

This is strong evidence for a specific group—but not a universal heart prevention strategy.

What the FDA approval means in the United States

In 2024, the U.S. Food and Drug Administration approved a new indication for Wegovy (semaglutide) to reduce the risk of major cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

This matters for two reasons:

It formally recognizes cardiovascular risk reduction—not just weight loss—as an approved use.
It allows clinicians to prescribe it specifically for heart risk reduction within labeled indications.

However, FDA approval does not guarantee insurance coverage. That depends on individual plans and federal policy.

How cardiology practice is evolving

The American Heart Association and other cardiology groups have highlighted the SELECT findings as important for secondary prevention in people with obesity and cardiovascular disease.

In practice, many cardiologists now consider GLP-1 therapy as an add-on option for appropriate patients—alongside:

Statins and other cholesterol-lowering medications
Antiplatelet therapy (such as aspirin, when indicated)
Blood pressure control
Smoking cessation
Physical activity and nutrition changes

Semaglutide does not replace these therapies. It builds on them.

Side effects and safety considerations

Like all medications, semaglutide has risks and side effects.

Common side effects:

Nausea
Vomiting
Diarrhea or constipation
Abdominal discomfort

These are usually more pronounced when starting treatment or increasing the dose and often improve over time.

Other safety considerations:

Gallbladder disease
Possible increased risk of pancreatitis (still monitored, though uncommon)
Thyroid C-cell tumor warning based on animal studies (contraindicated in people with certain rare thyroid cancer syndromes)

Patients with a history of pancreatitis, severe gastrointestinal disease, or certain endocrine conditions should discuss risks carefully with their clinician.

Cost and insurance: the reality in 2026

Cost remains one of the biggest barriers.

List prices for GLP-1 medications can exceed $1,000 per month without insurance. While many commercial insurance plans now cover Wegovy for weight management or cardiovascular risk reduction, coverage varies widely. Prior authorization is common.

Medicare is more complicated.

Under current federal law, Medicare Part D generally does not cover medications prescribed solely for weight loss. Even with the expanded cardiovascular indication, coverage decisions are shaped by statutory limits and evolving CMS policy. As of 2026, coverage remains inconsistent and is still a subject of national policy debate.

KFF (formerly the Kaiser Family Foundation) has reported that cost and coverage variability are major issues for patients, especially older adults and those on fixed incomes.

For many Medicare beneficiaries with heart disease—the very population at high cardiovascular risk—affordability is a central concern.

Equity and access: who may benefit—and who may be left out

Cardiovascular disease disproportionately affects lower-income communities and many Black and Hispanic populations in the United States.

If high-cost therapies are primarily accessible to people with generous commercial insurance, existing disparities could widen. Access depends on:

Insurance design
State Medicaid policies
Supply stability
Out-of-pocket affordability

Patients should not assume availability or coverage without checking directly with their insurer.

Questions to ask your clinician

If you have established cardiovascular disease and overweight or obesity, consider discussing:

Am I similar to the patients studied in the SELECT trial?
How much might this reduce my personal heart attack or stroke risk?
What side effects should I expect?
How would this interact with my current medications?
What happens if I stop the medication?
Will my insurance cover it, and what are the long-term costs?

This decision is not only about weight. It is about overall cardiovascular risk, long-term planning, and affordability.

What this means for readers

Semaglutide is supported by strong randomized trial evidence showing reduced heart attack and stroke risk in adults with overweight or obesity who already have cardiovascular disease and do not have diabetes.

That is meaningful—but specific.

It does not apply to everyone. It does not replace statins or other proven therapies. And cost and coverage remain major obstacles, particularly for Medicare beneficiaries.

If you have heart disease, this is worth a conversation with your clinician. The decision should weigh potential cardiovascular benefit, side effects, long-term commitment, and financial realities.

As with many advances in heart care, the science is strong. The real-world access questions are still catching up.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.